ArticleHuman vaccines & immunotherapeutics2025
Investigation and analysis of influencing factors on the economic burden of varicella disease in Qingyang, China, 2024.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Varicella epidemiology, susceptibility and cost burden in Chongqing China: implications for prevention and control strategies.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the economic burden and associated determinants of varicella cases in Qingyang City, Gansu Province, thereby informing the formulation and effectiveness evaluation of varicella prevention and control strategies. Based on socioeconomic and geographic characteristics, varicella cases reported in 2024 from Xifeng District, Heshui County, and Zhenyuan County were selected for cross-sectional surveys. The direct and indirect economic burdens were analyzed using Excel 2010 and SPSS 20.0 software. Univariate analysis (Wilcoxon/Kruskal-Wallis tests) was conducted to identify factors associated with economic burden, subsequently, binary Logistic regression was employed for multivariate analysis of significant variables. A total of 1,010 varicella cases were analyzed. Clinical characteristics revealed a mean disease duration of 10.33 ± 2.45 days and work loss time of 9.45 ± 4.38 days. Healthcare utilization included an average of 1.80 ± 1.15 medical visits and caregiver duration of 9.37 ± 2.46 days. The overall economic burden amounted to $283,428 (US), resulting in a per capita burden of $256 (IQR: $212-$345). Per capita total economic burdens for mild, moderate-severe, and hospitalized varicella cases were calculated as $172, $257 and $487, respectively (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.